TrialsgrambetaRCTs are beautiful

PROTECT

2023

Sparsentan in IgA Nephropathy

In 404 patients with IgA nephropathy and proteinuria despite maximal RAS blockade, sparsentan reduced proteinuria compared with irbesartan.

Result

Change in urine protein:creatinine ratio at week 36
Effect estimate

ratio0.5995% CI 0.51-0.69 · P < 0.0001

Also reported: eGFR chronic slope difference 1.1 mL/min/1.73m²/yr (95% CI 0.1–2.1; p=0.037) over 2 years.

Original publication
Subtopic
IgA nephropathy
Design
Phase 3 double-blind, active-controlled RCT
Relevance
Important: one of several pillars.
Source
Rovin BH, et al. Lancet. 2023;402(10417):2077-2090.doi 10.1016/S0140-6736(23)00569-X

Discussion & critique

Dual endothelin/angiotensin antagonism; supported accelerated then full FDA approval of Filspari for IgA nephropathy.

Discussed in podcasts